Phase Ib Study of VK-2019 for Relapsed or Refractory EBV+ DLBCL
This study is testing a new oral medication called VK-2019 for adults who have a type of blood cancer called Epstein-Barr Virus (EBV)-positive Diffuse Large B-cell Lymphoma (DLBCL) that has come back (relapsed) or has not responded to previous treatments (refractory). You might be able to join if you are at least 18 years old and have already tried at least two other treatments for your DLBCL. The main goal of this study is to find the safest dose of VK-2019. Participants will take VK-2019 daily in cycles of 28 days, and the study will look at how safe the drug is and if it causes any side effects. The study aims to enroll 30 participants, but its current recruitment status is unclear.
- Study design
- This is an open-label, dose-escalation Phase Ib study, meaning everyone knows what treatment is being given, and the dose of VK-2019 will be gradually increased in different groups of participants. The study plans to enroll 30 participants.
- What's involved
- You would take VK-2019 daily for 28-day cycles, continuing as long as your disease doesn't worsen or side effects are manageable. Your response to treatment will be checked every three cycles.
- Compensation
- Not stated in the trial record.
- Follow-up
- All participants will be followed for a total of 3 years after starting treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
At a glance
Conditions
NCT06789159
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Kentucky
Lexington, Kentuckyno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Pierluigi Porcu, MD · PRINCIPAL_INVESTIGATOR · University of Kentucky
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety Dose- Maximum Tolerated DoseAt the end of Cycle 1 (each cycle is 28 days), until disease progression or unacceptable toxicity. All Patients will be followed for a total of 3 years.
• The maximum tolerated dose (MTD) of single agent VK-2019 based upon treatment emergent AE (graded by the National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\], Version 5.0).